Greenwich LifeSciences is a thinly covered stock, and only two current, attributable analyst price targets could be verified. Noble Financial initiated coverage with a $45 target (Buy), while H.C. Wainwright's Yi Chen raised the firm's target from $50 to $69 in July 2026, also maintaining a Buy rating. The arithmetic mean of these two figures is $57, which is the central target used throughout this article; the low-to-high range is $45 to $69.
Because only two firms cover the name, there is no meaningful "consensus" in the usual sense. The wide gap between the two targets reflects how much of the valuation depends on assumptions about the Flamingo-01 Phase III trial. The higher H.C. Wainwright target embeds more confidence in a successful clinical outcome, while the lower Noble Financial figure is more conservative. Neither target should be read as a guarantee, and the average is best understood as a rough midpoint of a genuinely uncertain range rather than a precise forecast.
The stock closed near $15.17 on November 6, 2026, well below its 52-week high of $34.10 and above its 52-week low of $7.78. Reaching the $57 central target would require an upside of approximately 276%, which is a very large move by any standard and is particularly unusual for a company with no commercial product revenue yet.
The path toward that level is almost entirely event-driven. As a clinical-stage developer, Greenwich LifeSciences' valuation hinges on GLSI-100 (GP2 plus GM-CSF), an immunotherapy being evaluated in the Flamingo-01 Phase III trial to prevent breast cancer recurrence. Positive interim or final efficacy data would be the clearest catalyst for a re-rating, while negative or ambiguous data would likely invalidate the higher target and pressure the stock. Until data arrive, price movement is likely to remain volatile and sentiment-driven.
The $34.10 52-week high, set in late January 2026, is the most relevant overhead reference, and the $7.78 52-week low marks the major downside floor. The stock is currently trading in the lower half of that range after a choppy year in which it has declined about 28% year-to-date while still up sharply over the trailing 12 months. The $57 target sits far above any recent trading level, meaning there is no nearby technical path to it; the gap would need to be bridged by fundamental, catalyst-driven repricing rather than ordinary momentum.
Analyst price targets are typically set on a roughly 12-month research horizon, though neither covering firm has publicly tied its target to a specific date. The most important item to monitor is the progress and data timing of the Flamingo-01 Phase III trial, followed by the company's quarterly earnings updates, which for a pre-revenue biotech primarily reveal cash position, research and development spending, and clinical milestones. Investors should also watch for any analyst target revisions, financing announcements, and regulatory or FDA (Food and Drug Administration) interactions, all of which can materially shift the outlook.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing fundamental research, the tool is designed to help traders discover opportunities, keep an eye on existing positions, and identify shifting trends more efficiently. For investors tracking a volatile, event-driven name like GLSI, automated signal monitoring can serve as a useful complement to traditional research.
The $57 central target represents the average of just two verified analyst price targets, spanning a wide $45 to $69 range, and implies a roughly 276% advance from the recent price near $15.17. The case for such a move rests almost entirely on a successful Flamingo-01 Phase III outcome for GLSI-100, which would validate the company's lead immunotherapy and justify a substantial re-rating. The principal obstacles are equally clear: binary clinical risk, the absence of commercial revenue, ongoing cash needs, and potential dilution. Given the thin coverage and the extreme spread between targets, the $57 figure is best treated as a directional marker of analyst optimism rather than a precise or assured destination. Investors should focus on trial data and capital position above all else.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GLSI has been loosely correlated with IPSC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GLSI jumps, then IPSC could also see price increases.
| Ticker / NAME | Correlation To GLSI | 1D Price Change % | ||
|---|---|---|---|---|
| GLSI | 100% | -2.23% | ||
| IPSC - GLSI | 36% Loosely correlated | +1.23% | ||
| RXRX - GLSI | 35% Loosely correlated | -4.35% | ||
| ABUS - GLSI | 34% Loosely correlated | +1.49% | ||
| DMAC - GLSI | 34% Loosely correlated | -5.79% | ||
| RZLT - GLSI | 34% Loosely correlated | -5.56% | ||
More | ||||